Regeneron's unconventional, long-term R&D model
The guest argued Regeneron's founders built a unique, technology-driven model to solve the recurring pharma problem of patent cliffs by continuously inventing new medicines internally, rather than relying on expensive, low-return acquisitions.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.